The use of immune checkpoint inhibitors has emerged as an effective treatment option for patients with several tumor types. By increasing the activity of the immune system, they can induce inflammatory side effects, which are often termed immunerelated adverse events. These are pathophysiologically unique toxicities, compared with those from other anticancer therapies. In addition, the spectrum of the target organs is very broad. Immune-inflammatory adverse events can be life threatening. Prompt diagnosis and pharmacological intervention are instrumental to avoid progression to severe manifestations. Consequently, clinicians require new skills to successfully diagnose and manage these events. These SEOM guidelines have been developed with the consensus of ten medical oncologists. Relevant studies published in peer-review journals were used for the guideline elaboration. The Infectious Diseases Society of America grading system was used to assign levels of evidence and grades of recommendation.
Introduction: landscape of adverse events induced by cancer immunotherapies
The use of immune checkpoint inhibitors (ICI), such as inhibitors of cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death 1 (PD-1) or its ligand, programmed cell death ligand 1 (PD-L1), has emerged as effective treatment options for patients with several tumor types. By increasing the activity of the immune system, ICI can induce inflammatory side effects, which are often termed immune-related adverse events (irAEs). These are pathophysiologically unique toxicities compared with those from other anticancer therapies. The severity of irAEs is graded according to the Common Terminology Criteria for Adverse Events (CTCAE) [1, 2] .
The frequency of irAEs varies according to the specific class of compounds and patient population. Grade 3-4 toxicities have been reported in 10-27% of patients receiving anti-CTLA-4, and in 7-20% of patients receiving anti-PD-1/anti-PD-L1 agents [3] . Fatigue is a commonly reported toxicity, with a frequency of 12-37% of patients receiving an anti-PD-1/anti-PD-L1, and most of the times is not associated with a treatable reason [3] . These frequencies can increase significantly when these drugs are given in combination with another ICI or with chemotherapy [3, 4] . Not only the spectrum of target organs is very broad (Table 1) [5, 6] , but also the timing and temporal evolution of the irAEs. The latter also depends on the class of ICI, but, in general, skin toxicity can appear after 2 weeks, endocrine events can have a delayed onset and liver and gastrointestinal toxicities may arise at intermediate time points. All these toxicities can become accelerated when ICIs are combined. Consequently, clinicians require new skills to successfully diagnose and manage these events properly.
Several guidelines have been published [3, [7] [8] [9] ; for this reason, we will emphasize on key general points regarding the management of irAEs, including severe and/or treatment refractory irAEs.
Methodology
These SEOM guideline have been developed with the consensus of ten medical oncologists from Spanish Society of Medical Oncology (SEOM) and Spanish Group for Cancer Immune-Biotherapy (GÉTICA). Relevant studies published in peer-review journals were used for the elaboration of the guideline. The Infectious Diseases Society of America grading system was used to assign levels of evidence and grades of recommendation [10] .
General principles for the management of immune-related adverse events
Immune-inflammatory adverse events can be life threatening [11] . Prompt diagnosis and pharmacological intervention are instrumental to avoid progression to severe manifestations [V, A] [1, 7, 12] . For such purposes, sharing adequate information with patients and their families, other treating physicians (including primary care and emergency room), [12] . As shown in Table 2 , grade 2 irAEs usually require withholding ICI and close monitoring, and to decide if systemic corticosteroids (prednisone, initial dose of 0.5 to 1 mg/kg/ day, or equivalent) should be initiated [V, A] [7] . For most of the grade 1 irAEs, ICIs can be continued, with some exceptions (e.g., neurologic or cardiac toxicities) [7] . Grade 3-4 irAEs must be treated with high-dose corticosteroids (prednisone 1 to 2 mg/kg/day, or methylprednisolone IV 1 to 2 mg/kg/day) [V, A] [7] . Once initiated, corticosteroids should be tapered over 4-6 weeks. If there is no improvement after 48-72 h, consider other immunosuppressors [V, A] [7] (Table 3 ). Dose adjustments of ICIs are not recommended [7] . No prophylactic role has been demonstrated for steroids [II, D] [13] .
Patient selection and baseline assessments
Baseline assessments are recommended before starting treatment to rule out susceptibility to develop irAEs. These include a complete patient and family history, general physical condition, concomitant herbs and medication. Baseline laboratory tests may include complete blood counts, renal, liver and pancreatic functions tests, hormonal axis tests and viral serologies [V, C].
Due to ICI mechanism of action, several groups of patients have been excluded from clinical trials, including patients with chronic infectious diseases (hepatitis B and C, HIV), transplant recipients or patients with autoimmune (Table 3 ) (oral prednisone, iv methylprednisolone 1-2 mg/Kg/day) If no improvement in 2-3 days, add another immune suppressant ( Table 3 ), according to specific toxicity recommendations Once improved to at least G1, taper slowly (4-6 weeks)
Withhold immunotherapy until G1 without corticosteroids Consider PJP prophylaxis, calcium/vitamin D. Check blood glucose Grade 3-consider discontinuation of immunotherapy, depending on duration and target organ (see specific guidelines) Grade 4-discontinue immunotherapy 
Specific recommendations

Management of frequent toxicities
Management of gastrointestinal toxicity
Epidemiology Gastrointestinal toxicities are among the leading causes of immune-related adverse effects of ICIs.
The frequency with anti-CTLA-4 of diarrhea is 23-33% and 3-6% for grade 3-4 colitis, [16, 17] and with anti-PD-1/ PD-L1 the frequency of diarrhea is 11-19% and 1-4% for grade 3-4 colitis [18] ; the frequency of the combination anti-CTLA-4 and anti-PD-1/PDL1is up to 45%, grade 3/4, 9-11% [19] .
Clinical presentation
The median onset of diarrhea is approximately 6-8 weeks after initiation of therapy and 1/3 of patients have concurrent enteritis [12, 20] .
Diagnosis Diagnosis is based on duration, severity, and presence of alarm features that may require hospital admission [21] . Patients should undergo a complete blood count, serum electrolyte profile, serum albumin and serum C-reactive protein. Stool analyses for enteropathogens and Clostridium difficile toxin analysis should be carried out [20, 21] . Abdominal imaging is not routinely required in patients with grade 1-2 diarrhea. In severe cases, abdominal CT may be indicated to rule out complications [22] . Flexible sigmoidoscopy or colonoscopy should be performed in patients with bloody diarrhea or those with persistent ≥ grade 2 diarrhea [23] [IV, D].
Management See Fig. 1 [3 
Management of endocrine events
Epidemiology Endocrine AEs occur in 10% of patients receiving ICIs [33] . Hypophysitis is more frequent with anti-CTLA-4 and thyroid dysfunction with anti-PD-1/PD-L1 drugs. Other uncommon irAEs include primary adrenal insufficiency, Graves' disease, Graves' ophthalmopathy and autoimmune diabetes mellitus.
Clinical presentation Endocrine toxicities usually present with nonspecific symptoms that make them difficult to suspect and many of them are irreversible due to the permanent damage of the affected gland [34] . The most common are those affecting the thyroid gland, which are usually grade ≤ 2. These occur due to a transient inflammation of the gland, which can present with overproduction of thyroid hormone (hyperthyroidism) or underproduction (hypothyroidism). Fig. 3 [V, A] . Hyperthyroidism usually does not need active treatment, although it may evolve to hypothyroidism. Hypothyroidism is usually a permanent condition that needs levothyroxine substitution for life. Hypophysitis can affect one or several of the pituitary axes with or without a pathological image in the MRI. The steroid axis is the most frequently affected permanently [35] . In these patients, any additional stress can cause an acute adrenal crisis, seriously threatening patient's life and requiring urgent treatment. For grade ≥ 3 toxicity to seek endocrinology consultation is recommended.
Diagnosis and treatment See
Management of pneumonitis
Epidemiology Pneumonitis occurs predominantly in patients receiving anti-PD-1/PD-L1 alone or combination with anti-CTLA-4 [36] . The incidence is higher in patients with lung and renal cell cancer, suggesting that chemotherapy-induced lung inflammation, previous radiotherapy, pre-existing lung disease or smoking may contribute to the occurrence of this toxicity [37] .
Clinical presentation Pneumonitis can mimic other symptoms encountered in cancer patients including dyspnea and nonproductive cough. Fever and chest pain are less common.
Diagnosis Patients should undergo a chest CT scan as chest X-ray may fail to identify about 25% of cases of pneumonitis [38] . Several patterns of radiological presentation have been reported, being cryptogenetic organizing pneumonia the most frequent [36] . Infliximab and/or cyclophosphamide should be considered for refractory pneumonitis [3, [7] [8] [9] .
Management of cutaneous adverse events [39, 40]
Epidemiology Cutaneous side effects are common under ICIs (anti-CTLA-4: 43-45%, anti-PD-1/PD-L1: 35%), and may be serious and dose limiting. Cutaneous adverse events appear later with anti-PD-1/PD-L1 than with anti-CTLA-4 or combination.
Clinical presentation
The most frequently reported cutaneous adverse events are maculo-papular rash, pruritus and vitiligo. Exacerbation of psoriasis or psoriasiform and lichenoid reactions has also been reported. [46] .
Diagnosis
Management of less frequent toxicities
Management of cardiovascular toxicity
Epidemiology and clinical presentation The incidence of cardiac toxicity is < 1%, although it might have been underreported and/or underestimated. The incidence is higher with the combination of anti-CTLA-4 and anti-PD-1/PD-L1 (0.27%) compared with anti-PD-1/PD-L1 alone (0.06%). A wide range of toxicities, including myocarditis, pericarditis, arrhythmias, cardiomyopathy and decrease in ventricular function, have been reported [47] . [3] . Infliximab in contraindicated in the presence of moderate to severe heart failure.
Diagnosis and management
Management of renal toxicity
Epidemiology and clinical presentation Renal toxicity is rare in patients receiving monotherapy (< 1%) but can reach 5% when ICIs are combined together or with a platinumbased chemotherapy. The most common event is acute tubule-interstitial nephritis.
Diagnosis and management
Renal function should be measured before every infusion of ICI and nephrotoxic drugs may be stopped in case of renal dysfunction. Presence of infection or urinary tract obstruction must be evaluated. ICI should be interrupted in grade ≥ 2 renal dysfunction and treatment with high-dose steroids is recommended [V, B]. Nephrology evaluation is also recommended and a renal biopsy may be useful [V, B] [3, 48] .
Management of rheumatologic toxicity
Epidemiology and clinical presentation Incidence of rheumatologic toxicity is generally underestimated and is more common with anti-PD-1/PD-L1. They can be grouped in inflammatory arthritis, myositis, and polymyalgia rheumatica (PMR)-like syndromes [49] .
Diagnosis and management
A multidisciplinary approach would be the first measure. Comprehensive anamnesis including joint examination and muscle strength, autoimmune blood panels and inflammatory markers, and radiological assessment with plain-X ray, ultrasound and or MRI is recommended [50] [V, D]. For grade 1 events, common analgesia with paracetamol or NSAIDs is recommended. From ≥ grade 2, referral to rheumatologist, temporary or permanent discontinuation of ICIs, steroids and biologic disease-modifying anti-rheumatic drugs must be considered [51] [V, D].
Management of ocular toxicities
Epidemiology and clinical presentation Ocular toxicities represent < 1% of irAEs [52] and consist of ocular inflammation (uveitis, peripheral keratitis, Vogt-Koyanagi-Harada syndrome), orbital inflammation, as well as retinal and choroidal diseases (retinopathy, neovascularization) [53] . Previous trials have shown that patients who develop ocular toxicities are more likely to present other irAEs. Uveitis has been reported in patients treated with anti-CTLA-4 and anti-PD-1 [54] . Idiopathic orbital inflammation has been described in relation to ipilimumab [52, 55] . Choroidal neovascularization has been reported in a patient treated with ipilimumab [56] , requiring intravitreal anti-VEGF injections. 
Diagnosis and management
Management of refractory toxicities (Table 3)
Epidemiology of steroid-refractory high-grade irAEs is currently unknown. Due to the lack of validated biomarkers, a gradual approach is advocated to manage severe irAEs, starting with high-dose steroids. If the latter fails, a more aggressive immunosuppression is recommended, considering the introduction of cytokine-directed mAb against IL-1, IL-6 or TNFα [11, 57] . Anti-TNFα mAb infliximab (single dose of 5 mg/kg) is the upfront recommended treatment for corticosteroid-refractory colitis and pneumonitis, and mycophenolate mofetil with appropriate antibacterial and antiviral prophylaxis for corticosteroid-refractory hepatitis [V, C], although use of anti-IL6 (tocilizumab) and anti-IL1 (anakinra) may represent good alternatives for the previous and many other irAEs in the context of a personalized approach with close monitorization [7] [V, D]. Immunoglobulins and plasmapheresis could be an option in severe and multirefractory irAEs, especially in neurological irAEs [8] [IV, D].
Conclusions
ICIs are an effective treatment option in several tumor types that can induce inflammatory side effects, termed irAES. irAEs can affect multiple organs of the body and its severity can be low to life threatening. As a consequence, clinicians require new skills to successfully diagnose and manage these events, and also a multidisciplinary approach may be indicated.
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